In Phase C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, participants will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment until condition progression or perhaps the members are not able to tolerate the study drugs. For all move cytometry experiments, ten,000 cells for every replicate had been https://kemalg554ugs8.bloggadores.com/profile